Lal Tanwani, MD
Internal Medicine · Louisville, KYNPI 1336133347
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,623 of the $38,392 with a category attached, or 61.5%. 43 manufacturers reported payments, led by Boehringer Ingelheim at 33.5% of the total. Reporting peaked in 2019 at $11,890 and has fallen 85.7% since, to $1,698 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 561 payments — averaging $68.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$13K
- Esperion Therapeutics, Inc.$11K
- Lilly USA, LLC$7K
- Novo Nordisk$1K
- Insulet Corporation$871
- Sanofi-aventis U.S. LLC$696
- plus $5K from 37 others
What the payments were for
- Consulting fees$2,9258%
- Speaking & faculty fees$23,62362%
- Travel & lodging$1,3934%
- Food & beverage$10,37527%
- Education$460%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$17,759
- NEXLIZET$10,335
- NEXLETOL$10,335
- Omnipod$352
- iLet Bionic Pancreas$342
- t-slim insulin pump$300
- MYCAPSSA$139
- CRENESSITY$131
- TZIELD$126
- Yorvipath$125
- FreeStyle Libre$124
- PRALUENT$111
- FREESTYLE LIBRE 3$109
- MINIMED 780G$106
- Wegovy$106
How this compares
$38,392 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 391 | $459,369 |
| JardianceEmpagliflozin | 276 | $323,248 |
| JanuviaSitagliptin Phosphate | 275 | $302,275 |
| TrulicityDulaglutide | 221 | $264,217 |
| MounjaroTirzepatide | 200 | $241,032 |
| Tresiba Flextouch U-200Insulin Degludec | 100 | $131,622 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $121,736 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 79 | $110,756 |
| FarxigaDapagliflozin Propanediol | 95 | $94,688 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $61,053 |
| Humulin R U-500Insulin Regular, Human | 42 | $60,340 |
| Tresiba Flextouch U-100Insulin Degludec | 108 | $56,415 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 43 | $55,435 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 362 | $53,002 |
| Novolog FlexpenInsulin Aspart | 189 | $38,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev | $6,750 | $514,251432 claims |
| Novo NordiskOzempic, Novolog | $1,258 | $467,412412 claims |
| MerckJanuvia, Janumet Xr, Janumet | $210 | $385,574345 claims |
| Boehringer IngelheimJardiance | $12,877 | $323,248276 claims |
| AstraZenecaFarxiga | $254 | $94,68895 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $696 | $61,05360 claims |
| Johnson & JohnsonInvokana | $88 | $14,75317 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $6,392540 claims |
| AbbVieSynthroid | $12 | $5,27872 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Louisville
- Robert SasserLouisville$62K
- Kelley McIntyreLouisville$48K
- Mark WilliamsLouisville$33K
- Scott YoungLouisville$24K
- Frank SimonLouisville$22K
- Walter BruningLouisville$22K
- Brian ParadowskiLouisville$20K
- Suresh NairLouisville$20K
- Yiyi TsaiLouisville$19K
- Keith CarterLouisville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.